Biosimilars Rheumatology Roundup: June 2025

Biosimilars Account for 23% Market Share, With Wide Uptake Disparities Across Molecules

May 22nd 2024

By Skylar Jeremias

In the IQVIA Use of Medicines in the US 2024 report, biosimilars were found to be large contributors to lower drug costs and drivers of market growth; however, these products account for about 23% of the overall biologics market, showing wide variation in uptake across molecules.

DDW 2024 Posters Evaluate Safety, Efficacy, Impact of BMI on Zymfentra Use

May 21st 2024

By Skylar Jeremias

Posters from Digestive Disease Week (DDW) on the ongoing LIBERTY-CD trial assessing Zymfentra, a subcutaneous infliximab product, compared with intravenous infliximab treatment in Crohn disease show the safety and efficacy of the product, as well as the impact of body mass index (BMI) on clinical outcomes.

FDA Approves First Eylea Biosimilars

May 20th 2024

By Skylar Jeremias

The FDA approved the first 2 biosimilars referencing Eylea (aflibercept)—Yesafili (aflibercept-jbvf) and Opuviz (aflibercept-yszy)—for the treatment of ophthalmic conditions.

BioRationality: FDA Pridefully Declares 50th Biosimilar Approval

May 20th 2024

By Sarfaraz K. Niazi, PhD

Sarfaraz K. Niazi, PhD, congratulates the FDA on approving the 50th biosimilar, noting that there's more work to be done to expand the market.

Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report

May 19th 2024

By Skylar Jeremias

The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.

Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD

May 18th 2024

By Deana Ferreri, PhD

A real-world study in Spain on patients with inflammatory bowel disease (IBD) found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.

Optimizing Biosimilar Treatment Strategies in Bone Health

May 17th 2024

Colin C. Edgerton, MD, discusses key considerations for utilizing biosimilars in the bone health treatment landscape.

The Top 5 Biosimilar Articles for the Week of May 13

May 17th 2024

By Cameron Santoro

Here are the top 5 biosimilar articles for the week of May 13, 2024.

Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings

May 16th 2024

By Skylar Jeremias

Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.

Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars

May 15th 2024

By Skylar Jeremias

At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.